

# WEST

[Help](#)
[Logout](#)
[Interrupt](#)
[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show Numbers](#) | [Edit Numbers](#) | [Preferences](#) | [Index](#)

## Search Results -

Term	Documents
4.CLM. USPT.	29
(L4.CLM.).USPT.	29

Database: US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

Search:

L6

[Refine Search](#)

[Recall Text](#)

[Clear](#)

## Search History

DATE: Friday, November 14, 2003   [Printable Copy](#)   [Create Case](#)

Set Name Query  
side by side

Hit Count Set Name  
result set

DB=USPT; PLUR=YES; OP=ADJ

L6   L4.clm.

29   L6

DB=; PLUR=YES; OP=ADJ

L5   L4.clm.

80   L5

L4   b7\$ same (inhibit\$ or suppress\$ or antagoni\$ or block\$)

5215   L4

L3   L2 and b7\$

31   L3

L2   L1

73   L2

DB=USPT,PGPB; PLUR=YES; OP=ADJ

L1   linsley.in.

73   L1

END OF SEARCH HISTORY

## Search Results - Record(s) 1 through 10 of 31 returned.

- 
- ☐ 1. 20030119024. 19 Jul 02. 26 Jun 03. Genes and proteins associated with T cell activation. Linsley, Peter S., et al. 435/6; 435/320.1 435/372 435/69.1 530/350 536/23.5 C12Q001/68 C07H021/04 C07K014/705 C12N005/08 C12P021/02.
- 
- ☐ 2. 20030035816. 28 Jan 98. 20 Feb 03. SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF. PEACH, ROBERT JAMES, et al. 424/278.1; 435/320.1 435/325 435/69.1 530/351 536/23.5 C07H021/04 C12P021/06 A61K045/00 A61K047/00 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02 C07K001/00 C07K014/00 C07K017/00.
- 
- ☐ 3. 20020182211. 23 May 01. 05 Dec 02. Soluble CTLA4 mutant molecules and uses thereof. Peach, Robert J., et al. 424/143.1; 435/320.1 435/326 435/69.1 530/388.22 536/23.53 A61K039/395 C07H021/04 C07K016/28 C12N005/06 C12P021/02.
- 
- ☐ 4. 20020031510. 22 May 01. 14 Mar 02. Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith. Larsen, Christian P., et al. 424/131.1; 424/144.1 A61K039/395.
- 
- ☐ 5. 20020012989. 21 Mar 01. 31 Jan 02. Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell. Ledbetter, Jeffrey A., et al. 435/320.1; 435/455 435/456 C12N015/13.
- 
- ☐ 6. 6641809. 29 Mar 94; 04 Nov 03. Method of regulating cellular processes mediated by B7 and CD28. Linsley, Peter S., et al. 424/134.1; 424/192.1 435/252.3 435/320.1 435/471 514/2 514/8 514/885 530/350 530/387.3 536/23.1 536/23.4 536/23.5. A61K038/17 C07K014/705 C12N015/12 C12N015/63.
- 
- ☐ 7. 6623940. 13 Apr 00; 23 Sep 03. Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell. Ledbetter, Jeffrey A., et al. 435/69.1; 435/320.1 435/325 435/366 435/69.6 530/324 530/350 530/387.1 530/387.3 530/387.7. C12P021/00 C12P021/02 C12N005/10 C12N015/85 C07K016/28 C07K016/46.
- 
- ☐ 8. 6482919. 21 Mar 01; 19 Nov 02. Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell. Ledbetter, Jeffrey A., et al. 530/324; 530/327 530/328 530/329 530/330 530/350 530/387.1 530/387.3 530/387.9. C07K016/28 C07K014/705 C07K016/46.
- 
- ☐ 9. 6384198. 31 May 95; 07 May 02. Methods for inhibiting the production of HIV-1 retrovirus using monoclonal antibodies and Fv specific for CD2 antigen. Diegel, Michael L, et al. 530/390.1; 435/2 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. C07K016/28 C07K016/46 A01N001/02.
- 
- ☐ 10. 6183734. 10 Mar 95; 06 Feb 01. Inhibition of tumor cell growth by administration of B7-transfected cells. Chen, Lieping, et al. 424/93.21; 424/277.1 424/278.1 424/93.7 435/325. A01N063/00 A61K048/00.
-

Generate Collection

Print

**Search Results - Record(s) 11 through 20 of 31 returned.**

- 
- ☐ 11. [6132992](#). 05 Oct 95; 17 Oct 00. Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell. Ledbetter, Jeffrey A., et al. 435/69.7; 435/320.1 435/326 435/328 530/387.3 530/387.9. C12P021/02 C12N015/85 C07K016/28.
- 
- ☐ 12. [6090914](#). 15 Apr 94; 18 Jul 00. CTLA4/CD28Ig hybrid fusion proteins and uses thereof. Linsley, Peter S., et al. 530/350; 424/192.1 435/69.7 530/387.3. C07K019/00.
- 
- ☐ 13. [6004761](#). 02 Jun 95; 21 Dec 99. Method for detecting cancer using monoclonal antibodies to new mucin epitopes. Linsley, Peter S., et al. 435/7.23; 435/7.9 435/7.93 435/7.94 435/7.95 436/63 436/64 436/813. G01N033/574 G01N033/53.
- 
- ☐ 14. [5993800](#). 06 Jun 95; 30 Nov 99. Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand. Linsley, Peter S., et al. 424/93.21; 424/93.1 435/320.1 435/325 435/69.1 514/44. A61K048/00.
- 
- ☐ 15. [5977318](#). 07 Jun 95; 02 Nov 99. CTLA4 receptor and uses thereof. Linsley, Peter S., et al. 530/388.1; 424/141.1 424/143.1 435/331 435/334 530/388.15 530/388.73 530/861 530/866 530/868. C07K016/00.
- 
- ☐ 16. [5968510](#). 04 Oct 96; 19 Oct 99. CTLA4 receptor and uses thereof. Linsley, Peter S., et al. 424/141.1; 424/139.1 424/143.1 424/154.1 424/809 424/810 514/12 514/2 530/388.1 530/388.15 530/388.22 530/388.73. A61K039/395.
- 
- ☐ 17. [5916560](#). 20 Mar 97; 29 Jun 99. Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith. Larsen, Christian P., et al. 424/154.1; 424/130.1 424/139.1 424/143.1 424/153.1 424/173.1 514/2 514/8 530/387.3 530/388.73 530/388.75. C07K016/28.
- 
- ☐ 18. [5885796](#). 05 Jun 95; 23 Mar 99. CTLA4 receptor and uses thereof. Linsley, Peter S., et al. 435/69.1; 435/320.1 435/325 530/350 536/23.1 536/23.4 536/23.5. C12N021/02 C12N015/00 C07H021/00 C07K001/00.
- 
- ☐ 19. [5885579](#). 08 Jul 97; 23 Mar 99. CTLA4 receptor and uses thereof. Linsley, Peter S., et al. 424/192.1; 424/133.1 424/141.1 435/69.1 435/69.7 435/7.2 514/12 514/2 530/350 530/387.1 530/866 530/868. A61K039/00.
- 
- ☐ 20. [5851795](#). 02 Jun 95; 22 Dec 98. Soluble CTLA4 molecules and uses thereof. Linsley, Peter S., et al. 435/69.1; 435/252.3 435/320.1 435/325 435/69.7 530/350 530/367 530/387.3 536/23.1 536/23.4. A61K038/02 A61K039/395.
- 

Generate Collection

Print

Generate Collection

Print

**Search Results - Record(s) 21 through 30 of 31 returned.**

- ☐ 21. 5849876. 11 Jan 94; 15 Dec 98. Hybridomas producing monoclonal antibodies to new mucin epitopes. Linsley; Peter S., et al. 530/387.7; 424/155.1 424/156.1 424/157.1 424/174.1 435/330 435/344 435/344.1 435/70.21 530/388.8 530/388.85 530/389.7 530/391.3 530/391.7. A61K039/395 C07K016/00.
- ☐ 22. 5844095. 18 Jan 95; 01 Dec 98. CTLA4 Ig fusion proteins. Linsley; Peter S., et al. 530/387.3; 424/134.1 424/192.1 435/69.7. C07K019/00.
- ☐ 23. 5807734. 31 May 95; 15 Sep 98. Monoclonal antibodies and FV specific for CD2 antigen. Diegel; Michael L., et al. 435/252.33; 424/134.1 424/135.1 424/192.1 435/320.1 435/70.21 514/44 530/387.3 530/388.22 536/23.53. C07H021/04 C12N015/11 C12N001/20 C12N001/21.
- ☐ 24. 5795572. 25 May 93; 18 Aug 98. Monoclonal antibodies and FV specific for CD2 antigen. Diegel; Michael L., et al. 424/135.1; 424/133.1 424/141.1 424/143.1 424/154.1 424/156.1 424/178.1 530/387.3 530/388.1 530/388.22 530/391.3. C07K016/28 A61K039/395 A61K039/44 G01N033/53.
- ☐ 25. 5773253. 21 Jul 95; 30 Jun 98. MYPPPY variants of CTL A4 and uses thereof. Linsley; Peter S., et al. 435/69.7; 435/252.3 435/320.1 435/358 435/361 435/362 435/69.1 530/350 530/387.1 530/387.3 530/388.75 536/23.5. C12N015/12.
- ☐ 26. 5770197. 22 Jan 93; 23 Jun 98. Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules. Linsley; Peter S., et al. 424/134.1; 424/139.1 424/144.1 424/192.1 424/810 435/69.7 530/350 530/388.7 530/868. A61K039/395 C07K014/705 C07K016/46.
- ☐ 27. 5646002. 14 Feb 94; 08 Jul 97. Method for increasing the sensitivity of assays for target ligand. Linsley; Peter S., et al. 435/7.23; 435/18 435/7.1 436/543 436/64 436/813 436/825. G01N033/53.
- ☐ 28. 5637481. 13 Sep 93; 10 Jun 97. Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell. Ledbetter; Jeffrey A., et al. 435/69.6; 435/320.1 435/325 435/326 435/328 435/332 435/365 435/69.1 435/69.7. C12N015/79 C12N005/10 C12P021/00.
- ☐ 29. 5580756. 29 Mar 94; 03 Dec 96. B7IG fusion protein. Linsley; Peter S., et al. 435/69.7; 435/91.1 530/350 530/387.1 530/387.3 530/395 536/23.4. C12N015/62 A61K051/10.
- ☐ 30. 5521288. 29 Mar 94; 28 May 96. CD28IG fusion protein. Linsley; Peter S., et al. 530/387.3; 435/252.3 435/252.33 435/320.1 435/69.1 435/69.7 435/7.2 435/7.92 435/91.1 530/300 530/350 530/387.1 530/395 530/409 530/866 530/867 530/868 536/23.1 536/23.4 536/23.53. C07K016/46 C07K014/725 C07K014/00 C07H021/04.

Generate Collection

Print

[Generate Collection](#)[Print](#)**Search Results - Record(s) 31 through 31 of 31 returned.**

☐ 31. [5434131](#). 26 May 93; 18 Jul 95. Chimeric CTLA4 receptor and methods for its use. [Linsley, Peter S., et al.](#) 514/2; 424/133.1 514/12 530/350 530/866 530/868. A61K038/17 A61K039/395 C07K014/725 C07K019/00.

[Generate Collection](#)[Print](#)

Term	Documents
B7\$	0
B7	28607
B7A	159
B7AA	1
B7AALNCED	1
B7AA840	1
B7AA*J	1
B7AB	1
B7ABBL	1
B7ABBLE	1
B7ABBL-S	1
(L2 AND B7\$).	31

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)[Next Page](#)

[Generate Collection](#)[Print](#)

Term	Documents
B7\$	0
B7	28607
B7A	159
B7AA	1
B7AALNCED	1
B7AA840	1
B7AA*J	1
B7AB	1
B7ABBL	1
B7ABBLE	1
B7ABBL-S	1
(L2 AND B7\$).	31

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)[Next Page](#)

Generate Collection

L6: Entry 17 of 29

File: USPT

Oct 19, 1999

US-PAT-NO: 5968510

DOCUMENT-IDENTIFIER: US 5968510 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: October 19, 1999

## INVENTOR-INFORMATION:


NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA		
Ledbetter; Jeffrey A.	Seattle	WA		
Damle; Nitin K.	Hopewell	NJ		
Brady; William	Bothell	WA		
Kiener; Peter A.	Edmonds	WA		

US-CL-CURRENT: 424/141.1; 424/139.1, 424/143.1, 424/154.1, 424/809, 424/810, 514/12, 514/2, 530/388.1, 530/388.15, 530/388.22, 530/388.73

## CLAIMS:

What is claimed is:

1. A method for regulating CTLA4 positive T cell interactions with B7 positive B cells comprising contacting CTLA4-positive T cells with a monoclonal antibody, Fab or F(ab')<sub>2</sub> fragments reactive with CTLA4 thereby inhibiting interaction of CTLA4-positive T cells with B7 positive B cells and thus regulating CTLA4-positive T cell interactions with B7 positive B cells.

Generate Collection

L6: Entry 20 of 29

File: USPT

Mar 23, 1999

US-PAT-NO: 5885579

DOCUMENT-IDENTIFIER: US 5885579 A

TITLE: CTLA4 receptor and uses thereof

DATE-ISSUED: March 23, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA		
Ledbetter; Jeffrey A.	Seattle	WA		
Damle; Nitin K.	Hopewell	NJ		
Brady; William	Bothell	WA		
Kiener; Peter A.	Edmonds	WA		

US-CL-CURRENT: 424/192.1, 424/133.1, 424/141.1, 435/69.1, 435/69.7, 435/7.2, 514/12, 514/2, 530/350, 530/387.1, 530/866, 530/868

## CLAIMS:

What is claimed is:

1. A method for regulating functional CTLA4 positive T cell interactions with B7 positive cells comprising contacting the B7 positive cells with a ligand for the B7 antigen, in a amount effective to interfere with reaction of endogenous B7 antigen with CTLA4, wherein the ligand is a soluble CTLA4 molecule.
2. The method of claim 1, wherein said B7 positive cells are B cells.
3. The method of claim 1, wherein the interaction of said CTLA4-positive T cells with said B7 positive cells is inhibited.
4. A method for treating immune system diseases mediated by T cell interactions with B7 positive cells comprising administering to a subject a ligand for B7 antigen, in an amount effective to regulate T cell interactions with said B7 positive cells.
5. The method of claim 4, wherein said T cell interactions are inhibited.
6. A method for regulating functional CTLA4 positive T cell interactions with B7 positive cells comprising contacting the B7 positive cells with a ligand for the B7 antigen to interfere with reaction of endogenous B7 antigen, in an amount effective with CTLA4, wherein the ligand is CTLA4-E7.
7. A method for regulating functional CTLA4 positive T cell interactions with B7 positive cells comprising contacting the B7 positive cells with a ligand for the B7 antigen to interfere with reaction of endogenous B7 antigen, in an amount effective with CTLA4, wherein the ligand is CTLA4-p97.
8. A method for regulating functional CTLA4 positive T cell interactions with B7 positive cells comprising contacting the B7 positive cells with a ligand for the B7 antigen to interfere with reaction of endogenous B<sup>sup</sup>.17 antigen, in an amount effective with CTLA4, wherein the ligand is CTLA4-env gp120.
9. A method for treating immune system diseases mediated by T cell interactions with B7 positive cells comprising administering to a subject a ligand for the B7



antigen, in an amount effective to regulate T cell interactions with said B7 positive cells, wherein the ligand is CTLA4-E7.

10. A method for treating immune system diseases mediated by T cell interactions with B7 positive cells comprising administering to a subject a ligand for the B7 antigen, in an amount effective to regulate T cell interactions with said B7 positive cells, wherein the ligand is CTLA4-P97.

11. A method for treating immune system diseases mediated by T cell interactions with B7 positive cells comprising administering to a subject a ligand for the B7 antigen, in an amount effective to regulate T cell interactions with said B7 positive cells, wherein the ligand is CTLA4-env gp120.

Generate Collection

L6: Entry 24 of 29

File: USPT

Jun 23, 1998

US-PAT-NO: 5770197

DOCUMENT-IDENTIFIER: US 5770197 A

TITLE: Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules

DATE-ISSUED: June 23, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Linsley; Peter S.	Seattle	WA		
Ledbetter; Jeffrey A.	Seattle	WA		
Damle; Nitin K.	Renton	WA		
Brady; William	Bothell	WA		
Wallace; Philip M.	Seattle	WA		

US-CL-CURRENT: 424/134.1; 424/139.1, 424/144.1, 424/192.1, 424/810, 435/69.7, 530/350, 530/388.7, 530/868

## CLAIMS:

What is claimed is:

1. A method for suppressing an immune response comprising contacting B7-positive lymphocytes with a B7-binding molecule and an IL4-binding molecule, wherein an immune response is thereby suppressed.
2. The method of claim 1, wherein the immune response is a B cell response.
3. The method of claim 1, wherein the immune response is a T cell response.
4. A method for inhibiting tissue transplant rejection by a subject, the subject being a recipient of transplanted tissue, which method comprises administering to the subject a B7-binding molecule and an IL4-binding molecule so a primary and secondary immune response is suppressed thereby inhibiting tissue transplant rejection by the subject.
5. A method for inhibiting graft versus host disease in a subject which method comprises administering to the subject a B7-binding molecule and an IL4-binding molecule so a primary and secondary immune response is suppressed thereby inhibiting tissue transplant rejection by the subject.
6. The method of claim 1, 4, or 5, wherein the B7-binding molecule is a CTLA4Ig fusion protein.
7. The method of claim 6, wherein the CTLA4Ig fusion protein is a fusion protein having a first amino acid sequence containing amino acid residues from position 1 to position 125 of the amino acid sequence corresponding to the extracellular domain of CTLA4 and a second amino acid sequence containing amino acid residues corresponding to the hinge, CH2 and CH3 regions of human immunoglobulin C.gamma.1.
8. The method of claim 1, 4, or 5, wherein the B7-binding molecule is a CD28Ig/CTLA4Ig fusion protein hybrid.
9. The method of claim 8, wherein the CD28Ig/CTLA4Ig fusion protein hybrid is a fusion protein hybrid having a first amino acid sequence consisting of a portion

of the extracellular domain of CD28 receptor which portion binds B7 fused to a second amino acid sequence consisting of a portion of the extracellular domain of CTLA4 receptor which portion binds B7 and a third amino acid sequence of the hinge, CH2 and CH3 regions of human immunoglobulin C.gamma.1.

10. The method of claim 1, 4, or 5, wherein the IL4-binding molecule is a monoclonal antibody which specifically recognizes and binds to IL4.

11. The method of claim 1, 4, or 5, wherein the IL4-binding molecule is a soluble IL4 receptor which recognizes and binds to IL4.